Hemispherx Biopharma (HEB) Reports Q2 Loss of $0.04/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HEB Hot Sheet
Join SI Premium – FREE
Hemispherx Biopharma (NYSE: HEB) reported Q2 EPS of ($0.04), versus ($0.05) reported last year.
For earnings history and earnings-related data on Hemispherx Biopharma (HEB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lemaitre Vascular (LMAT) Misses Q3 EPS by 4c ; Offers Guidance
- Centrus Energy (LEU) Misses Q3 EPS by 48c ; Offers Guidance
- Tutor Perini (TPC) Tops Q3 EPS by 92c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
